Correspondence 0001104659-24-085440 from AEON Biopharma, Inc. (AEON) (CIK 0001837607) (AEON)
AEON Biopharma, Inc. (AEON) (CIK 0001837607)
Date: Aug. 2, 2024 · CIK: 0001837607 · Accession: 0001104659-24-085440
AI Filing Summary & Sentiment
File numbers found in text: 333-274094
Letter
Re: AEON Biopharma, Inc.
August 2, 2024
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549-6010
Registration Statement on Form S-1, as amended (File No. 333-274094)
Request for Acceleration of Effective Date
To the addressee set forth above:
In accordance with Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration by the Securities and Exchange Commission (the “Commission”) of the effective date of the above-referenced Registration Statement on Form S-1 (as amended, the “Registration Statement”) of AEON Biopharma, Inc. We respectfully request that the Registration Statement become effective as of 4:00 p.m., Washington, D.C. time, on August 5, 2024, or as soon as practicable thereafter.
The Company requests that we be notified of such effectiveness by a telephone call to Drew Capurro of Latham & Watkins LLP at (714) 755-8008 or, in his absence, Eric Hanzich of Latham & Watkins LLP at (714) 755-8234 and that such effectiveness also be confirmed in writing.
Sincerely,
/s/ Marc Forth
Show Raw Text
CORRESP
1
filename1.htm
August 2, 2024
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549-6010
Re: AEON Biopharma, Inc.
Registration Statement on Form S-1, as amended (File No. 333-274094)
Request for Acceleration of Effective Date
To the addressee set forth above:
In accordance with Rule 461 under the Securities
Act of 1933, as amended, we hereby request acceleration by the Securities and Exchange Commission (the “Commission”)
of the effective date of the above-referenced Registration Statement on Form S-1 (as amended, the “Registration Statement”)
of AEON Biopharma, Inc. We respectfully request that the Registration Statement become effective as of 4:00 p.m., Washington, D.C.
time, on August 5, 2024, or as soon as practicable thereafter.
The Company requests that we be notified of such
effectiveness by a telephone call to Drew Capurro of Latham & Watkins LLP at (714) 755-8008 or, in his absence, Eric Hanzich
of Latham & Watkins LLP at (714) 755-8234 and that such effectiveness also be confirmed in writing.
Sincerely,
/s/ Marc Forth
Marc Forth
Chief Executive Officer
AEON Biopharma, Inc.
cc:
Via Email
Alex Wilson, AEON Biopharma, Inc.
B. Shayne Kennedy, Esq., Latham & Watkins LLP
Drew Capurro, Esq., Latham & Watkins LLP
Eric Hanzich, Esq., Latham & Watkins LLP